EBOV-Specific Immune Profiling
Cross-source consensus on EBOV-Specific Immune Profiling from 1 sources and 6 claims.
1 sources · 6 claims
How it works
Preparation
Other
Other
Highlighted claims
- Aim 3 recruits EVD survivors with uveitis and EVD survivors without uveitis for immune profiling. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
- Ocular fluid samples are collected from EVD survivors with uveitis, while those without uveitis provide peripheral blood only. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
- Flow cytometry is used to characterize T-cell populations and activation status. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
- High-throughput RNA sequencing of lymphocyte receptor sequences is performed on cells from undiluted vitreous samples. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
- EBOV antigen specificity is assessed with antigen tetramers or intracellular cytokine staining after peptide stimulation against GP, NP, and VP40. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
- Cross-compartment comparison is intended to detect EBOV-specific lymphocyte clonotypes in the eye as evidence of active local immune engagement. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation